维普中文期刊产品整合服务
131篇 您的检索式:作者名="Haba A"
    题名 作者 年代 出处 被引量
1Retrospective cohort study Lower incidence of complications in endoscopic nasobiliary drainage for hilar cholangiocarcinoma显示文摘AIM:To identify the most effective endoscopic biliary drainage technique for patients with hilar cholangiocarcinoma.METHODS:In total,118 patients with hilar cholangiocarcinoma underwent endoscopic management[endoscopic nasobiliary drainage(ENBD)or endoscopic biliary stenting]as a temporary drainage in our institution between 2009 and 2014.We retrospectively evaluated all complications from initial endoscopic drainage to surgery or palliative treatment.The risk factors for biliary reintervention,post-endoscopic retrograde cholangiopancreatography(post-ERCP)pancreatitis,and percutaneous transhepatic biliary drainage(PTBD)were also analyzed using patient-and procedure-related characteristics.The risk factors for bilateral drainage were examined in a subgroup analysis of patients who underwent initial unilateral drainage.RESULTS:In total,137 complications were observed in92(78%)patients.Biliary reintervention was required in 83(70%)patients.ENBD was significantly associated with a low risk of biliary reintervention[odds ratio(OR)=0.26,95%CI:0.08-0.76,P=0.012].Post-ERCP pancreatitis was observed in 19(16%)patients.An absence of endoscopic sphincterotomy was significantly associated with post-ERCP pancreatitis(OR=3.46,95%CI:1.19-10.87,P=0.023).PTBD was required in 16(14%)patients,and Bismuth type III or IV cholangiocarcinoma was a significant risk factor(OR=7.88,95%CI:1.33-155.0,P=0.010).Of 102 patients with initial unilateral drainage,49(48%)required bilateral drainage.Endoscopic sphincterotomy(OR=3.24,95%CI:1.27-8.78,P=0.004)and Bismuth II,III,or IV cholangiocarcinoma(OR=34.69,95%CI:4.88-736.7,P<0.001)were significant risk factors for bilateral drainage.CONCLUSION:The endoscopic management of hilar cholangiocarcinoma is challenging.ENBD should be selected as a temporary drainage method because of its low risk of complications.Kazumichi Kawakubo Hiroshi Kawakami Masaki Kuwatani Shin Haba Taiki Kudo Yoko A Taya Shuhei Kawahata Yoshimasa Kubota Kimitoshi Kubo Kazunori Eto Nobuyuki Ehira Hiroaki Yamato Manabu Onodera Naoya Sakamoto 2016World Journal of Gastrointestinal Endoscopy2016,8,9:26
2Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin显示文摘Takahashi N Kawanishi Tabata R Haba A Tabata M Haruta Y Tsai H 2001Clin Cancer Res2001,7,:1
3Local expression of the serum amyloid A and formyl pepfide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis显示文摘O'HABA R MURPHY E P WHITEHEAD A S 2004Arthritis Rheum2004,50,6:1
4Angiogenesis and metastasis marker of human tumors 显示文摘Seon BK Takahashi N Haba A 2001Rinsho Byori2001,49,10:1
5Endoglin-targeted cancer therapy显示文摘SEON B K HABA A MATSUNO F 2011Curt Drug Deliv2011,8,1:1
6Nuclear factor of activated T-cells isoform c4 (NFATc4/NFAT3) as a mediator of antiapoptotic transcription in NMDA receptor-stimulated cortical neurons 显示文摘Vashishta A Habas A Pruunsild P 2009J Neurosci2009,29,15:1
7Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin显示文摘Takahashi N Kawanishi Tabata R Haba A 2001Clin Cancer Res2001,7,3:1
8Antiangiogenic therapyof established tumors in human skin/severe combined immunodeficiencymouse chimeras by anti-endo^in ( CD105) monoclonal antibodies, andsynergy between anti-endoglin antibody and cyclophosphamide显示文摘Takahashi N Haba A Matsuno F 2001Canc-er Res2001,61,21:1
9Shape control of colloidal metal nanocrystals显示文摘Tao A R Habas S Yang P 2008Small2008,4,:1
10GenoType MTBDRplus Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Strains and Clinical Samples 显示文摘A Lacoma N Garcia-Sierra C Prat J Ruiz-Manzano L Haba S Ros6s J Maldonado J Dominguez 2008J Clin Microbiol2008,46,11:1
11Preparation of poly (ethylene glycol) -modified poly (amido amine) den-drimers encapsulating gold nanoparticles and their heat-genera- ting ability 显示文摘HABA Y KOJIMA C HARADA A 2007Langmuir2007,23,10:1
12Training neural network classifiers for medical decision making:the effects of imbalanced datasets on classification performance显示文摘MAZUROWSKI M A HABAS P A ZURADA J M 2008Neural Net- works2008,21,23:1
13Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies,and synergy between anti-endoglin antibody and cyclophosphamide显示文摘Takahashi N Haba A Matsuno F 2001Cancer Res2001,61,:1
14Ciliary neuro-trophic factor mediates dopamine D2 receptor-induced CNS neuro-genesis in adult mice显示文摘Yang P Arnold SA Habas A Hetman M Hagg T 0,,:1
15Association of serum endoglin with metastasis in patients with colorectal,breast,and other solid tumors,and suppressive effect of chemotherapy on the serum endoglin显示文摘Takahashi N Kawanishi-Tabata R Haba A 2001Clin Cancer Res2001,7,3:1
16Shape control of colloidal metal nanocrystals显示文摘Tap A R Habas S Yang P D 2008Small2008,4,3:1
17Angiogenesis and metastasis marker of human tumor显示文摘Seon BK Takahashi N Haba A 2001Rinsho Byori2001,49,10:1
18Association of serum endoglin with metastasis in patients with coloectal,breast and other solid tumors and suppressive effect of chemotherapy on the serum endoglin显示文摘 Kawanishi TR Haba A 2001Clin Cancer Res2001,,7:1
19Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal anti-bodies,and synergy between anti-endoglin antibody and cyclophosphamide显示文摘Takahashi N Haba A Matsuno F 2001Cancer Res2001,61,21:1
20Association of serum endoglin with metastasis in patients with colorectal, breast,and other solid tumors,and suppressive effect of chemotherapy on the serum endoglin显示文摘Takahashi N Kawanishi-Tabata R Haba A 2001Clin Cancer Res2001,7,3:1
返回顶部 每页显示:
共7页 首页 上一页 第1页 下一页 末页 /7 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费